Literature DB >> 17502896

Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation.

J-C Meniane, J El-Cheikh, C Faucher, S Fürst, R Bouabdallah, D Blaise, M Mohty.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17502896     DOI： 10.1038/sj.bmt.1705702

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Disease control should be the goal of therapy for WM patients.

Authors:  Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2017-11-28

2.  Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

Authors:  Robert F Cornell; Veronika Bachanova; Anita D'Souza; Kwang Woo-Ahn; Michael Martens; Jiaxing Huang; A Samer Al-Homsi; Saurabh Chhabra; Edward Copelan; Miguel-Angel Diaz; Cesar O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mehdi Hamadani; Gerhard Hildebrandt; Rammurti T Kamble; Mohamed Kharfan-Dabaja; Tamila Kindwall-Keller; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard F Olsson; Ayman Saad; Saad Usmani; David H Vesole; Jean Yared; Tomer Mark; Yago Nieto; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-24       Impact factor: 5.742

3.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Alice Garnier; Marie Robin; Fabrice Larosa; Jean-Louis Golmard; Steven Le Gouill; Valérie Coiteux; Reza Tabrizi; Claude-Eric Bulabois; Victoria Cacheux; Mathieu Kuentz; Brigitte Dreyfus; Peter Dreger; Bernard Rio; Marie-Pierre Moles-Moreau; Karin Bilger; Jacques-Olivier Bay; Véronique Leblond; Didier Blaise; Olivier Tournilhac; Nathalie Dhédin
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.